89Zr-TLX250 PET/CT

Phase 3

Telix Pharmaceuticals Ltd (TLX)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

4mo

TLXPhase 3$2.6B

89Zr-TLX250 PET/CT Phase 3 Results Expected

89Zr-TLX250 PET/CT• Clear Cell Renal Cell Carcinoma82

Jun 30Estimated

CT.gov

00%

Competitive Landscape

1 competitor in Clear Cell Renal Cell Carcinoma

CRSPCTX131

Phase 2

View Full Landscape

Drug Information

Target Indication

Clear Cell Renal Cell Carcinoma

Clinical Trial

NCT06750419

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

TLX

Telix Pharmaceuticals Ltd

Biotechnology•North America•NASDAQ

Related Pipeline

Standard of CarePhase 3

Metastatic Prostate Cancer

177Lu-TLX591Phase 3

Metastatic Castration-resistant Prostate Cancer

68Ga-PSMA-11Phase 3

Biochemical Recurrence of Malignant Neoplasm of Prostate

EnzalutamidePhase 3

Metastatic Castration-resistant Prostate Cancer

177Lu-DOTA-TLX591Phase 2

Prostate Cancer

View full pipeline